Our news journalists obtained a quote from the research from the University of Southern California, "Here, we evaluated the therapeutic potential of interleukin (IL)-8 in lymphatic regeneration independent of its pro-inflammatory activity. We found that IL-8 promoted proliferation, tube formation, and migration of lymphatic endothelial cells (LECs) without activating the VEGF signaling. Additionally, IL-8 suppressed the major cell cycle inhibitor CDKN1C/p57(KIP2) by downregulating its positive regulator PROX1, which is known as the master regulator of LEC-differentiation. Animal-based studies such as matrigel plug and cornea micropocket assays demonstrated potent efficacy of IL-8 in activating lymphangiogenesis in vivo. Moreover, we have generated a novel transgenic mouse model (K14-hIL8) that expresses human IL-8 in the skin and then crossed with lymphatic-specific fluorescent (Prox1-GFP) mouse. The resulting double transgenic mice showed that a stable expression of IL-8 could promote embryonic lymphangiogenesis. Moreover, an immunodeficient IL-8-expressing mouse line that was established by crossing K14-hIL8 mice with athymic nude mice displayed an enhanced tumor-associated lymphangiogenesis. Finally, when experimental lymphedema was introduced, K14-hIL8 mice showed an improved amelioration of lymphedema with an increased lymphatic regeneration."
According to the news editors, the research concluded: "Together, we report that IL-8 can activate lymphangiogenesis in vitro and in vivo with a therapeutic efficacy in post-surgical lymphedema."
For more information on this research see: Interleukin-8 reduces post-surgical lymphedema formation by promoting lymphatic vessel regeneration. Angiogenesis, 2013;16(1):29-44. Angiogenesis can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Angiogenesis - www.springerlink.com/content/0969-6970/)
Our news journalists report that additional information may be obtained by contacting I. Choi, Dept. of Surgery, Norris Comprehensive Cancer Center, University of Southern California, 1450 Biggy St NRT6501, Mail Code 9601, Los Angeles, CA, 90033, United States.
Publisher contact information for the journal Angiogenesis is: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Cytokines, California, Los Angeles, Angiogenesis, Interleukins, United States, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.